Cervix, Phase II

A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate in Patients With Recurrent or Persistent Cervical Cancer

Volunteers
Health Professionals

What is the purpose of this trial?

This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent cervical cancer.

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Lisa Baker

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Alessandro Santin, MD
Professor of Obstetrics, Gynecology, and Reproductive Sciences; Clinical Research Team Leader, Gynecologic Oncology, Yale Cancer Center; Co-Chief, Section of Gynecologic Oncology

Sub-Investigators

Last Updated
02/01/2024
Study HIC
#2000023639